Advertisement

Search Results

Advertisement



Your search for ,ITS matches 8694 pages

Showing 7801 - 7850


issues in oncology

Building a Better Federal Oncology Workforce

The process of delivering novel treatments for patients with cancer involves a multifaceted and long-term interaction between three distinct entities: clinical researchers, who conduct the trials which test treatments; drug developers, including the pharmaceutical industry, which takes cancer drugs ...

palliative care

The Mechanisms Driving Cancer Pain

For over a decade, Patrick W. ­Mantyh, PhD, JD, has been investigating the molecular and cellular mechanisms that are involved in cancer-related pain, especially bone pain caused by advanced breast, prostate, and lung cancers. His early laboratory work using mouse models of bone cancer led to an...

issues in oncology

8 Steps to Help Children Cope With Cancer and Its Treatment

Here are several steps for helping pediatric and adolescent patients to cope with cancer and its treatment. Give young patients control whenever possible, suggests Shawna Grissom, MS, CCLS, CEIM, Director of the Child Life Program at St. Jude Children’s Research Hospital, and offer them realistic...

issues in oncology

Taking the Trauma Out of Cancer Care for Children and Adolescents

Getting a cancer diagnosis and going through treatment are difficult for patients of any age, but the experience can be especially traumatizing for the nearly 16,000 infants, children, and adolescents diagnosed each year with cancer,1 especially during the early days of treatment. Young cancer...

lymphoma

Clinical Trials Actively Recruiting Patients With Cutaneous Lymphoma

The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies for patients with newly diagnosed or relapsed or refractory lymphoma of the skin. The studies include observational, phase I, and phase II trials investigating single-agent and...

issues in oncology

In Search of Meaning: A Personal Journey

A famous Talmudic question asks: “What is truer than the truth?” The answer: “The story.” This is the story of my personal journey in search of meaning and the development of an approach to care for patients with advanced cancer, which I came to call “meaning-centered psychotherapy.” In terms of...

Mario R. Capecchi, PhD, Recognized With AACR Lifetime Achievement in Cancer Research Award

Mario R. Capecchi, PhD, was honored for his tremendous scientific contributions, which have had a profound impact on the understanding of cancer, with the 12th annual American Association for Cancer Research (AACR) Award for Lifetime Achievement in Cancer Research at the AACR Annual Meeting 2015....

skin cancer

Pembrolizumab vs Ipilimumab: Good vs Better

The treatment landscape for metastatic melanoma has recently undergone a remarkable transformation. Prior to 2011, clinicians and patients were presented with difficult decisions between therapies without proven survival benefit. Now, similarly difficult but much more hopeful choices are posed...

James Allison, PhD, Receives 2015 AACR Pezcoller Award

James Allison, PhD, was named a recipient of the 2015 Pezcoller Foundation–American Association for Cancer Research (AACR) International Award for Cancer Research at the 2015 AACR Annual Meeting. Dr. Allison, Chair of Immunology at The University of Texas MD Anderson Cancer Center, was acknowledged ...

supportive care
survivorship

Physiatry Has Become a Valuable Component of Survivorship Care in Cancer Centers

The role of a physical medicine and rehabilitation physician at cancer centers continues to grow, as survivors live longer and national cancer organizations advocate for more rehabilitation services throughout the continuum of survivorship care. Working with physiatrists at your institution can...

breast cancer

A Closer Look at the Disparities in Breast Cancer Outcome by Race and Ethnicity

The report from Dr. Steven Narod and colleagues recently published in JAMA1 and reviewed in this issue of The ASCO Post adds to the growing evidence regarding observed disparities in breast cancer outcomes by race and ethnicity among women in the United States. Since 1990, breast cancer death rates ...

breast cancer

Optimizing Treatment for Small, Lymph Node–Negative, HER2-Overexpressing Breast Cancers

Large, randomized phase III clinical trials showed that the addition of HER2-targeted therapy to chemotherapy for patients with early-stage, HER2-overexpressing breast cancers substantially decreased the risk of recurrence and improved survival. The chemotherapy given in these trials varied, but it ...

breast cancer

Increased Risk of Secondary Bone Marrow Neoplasia After Adjuvant Breast Cancer Treatment: Risk/Benefit Analysis and Biologic Insights

Ever since the early application of adjuvant chemotherapy for breast cancer decades ago, it has been recognized that there is always a price to pay for its success in reducing breast cancer mortality. Most of that “cost” is commonly considered in terms of the potential morbid short- and long-term...

integrative oncology

Maitake

The use of dietary supplements by patients with cancer has increased significantly over the past 2 decades despite insufficient evidence of safety and effectiveness. Finding reliable sources of information about dietary supplements can be daunting. Patients typically rely on family, friends, and...

ASCO Announces New Class of Participants in Quality Training Program

ASCO has announced the second class of oncology practices for its Quality Training Program. Twelve practices across the United States will participate in this 6-month comprehensive course, which will guide them through quality improvement activities using proven innovative learning techniques....

June McKoy Named to NCI Council of Research Advocates

June McKoy, MD, MPH, JD, LLM, MBA, Associate Professor of Medicine and Preventive Medicine at Northwestern University Feinberg School of Medicine and Director of Geriatric Oncology for the Lurie Cancer Center, has been selected by National Cancer Institute (NCI) Director, ­Douglas Lowy, MD, to join ...

Taking the Next Step in a Storied Career

On March 31, 2015, Harold Varmus, MD, left his position as Director of the National Cancer Institute (NCI) to join the faculty of Weill Cornell Medical College in New York as its Lewis Thomas University Professor of Medicine. Dr. Varmus was also named Senior Associate Core Member of the New York...

Exploring the History and Psychology of Pain: Beyond the Clinical Setting

BOOKMARKTitle: The Story of Pain: From Prayer to PainkillersAuthor: Joanna BourkePublisher: Oxford University PressPublication date: 2014Price: $34.95: hardcover, 416 page   “Pain may even kill. It may overwhelm the nervous system by its mere magnitude & duration.” —Peter Mere Latham, 1871...

cns cancers

Will the PVS-RIPO Poliovirus Be a Game Changer in the Treatment of Recurrent Glioblastoma?

Although the idea of using viruses to target cancer cells dates back more than 100 years, technologic advances in the genetic engineering of viruses are now making it possible to safely test oncolytic virotherapy as a valid strategy against cancer cells. One type of genetically engineered virus...

prostate cancer

MAINSAIL Trial: Worse Outcomes With Addition of Lenalidomide to Docetaxel-Prednisone in Prostate Cancer

The combination of docetaxel plus prednisone has been a standard therapy in advanced prostate cancer since 2004.1 Since then, there have been multiple randomized phase III trials comparing this standard of care with additional drug therapy. None has demonstrated improvement in outcome. Lenalidomide ...

hematologic malignancies

Answers: Case Report on Chronic Myelogenous Leukemia

Question 1: In the current era of tyrosine kinase inhibitor therapy, which prognostic model is best to assess the prognosis of a person with a new diagnosis of CML? Correct Answer: D. All of the above Expert Perspective Despite not being perfect, all of these scores are reasonably effective at...

prostate cancer
survivorship

Prostate Cancer Survivorship: Identifying Opportunities for Improvement

Prostate cancer survivors currently approach 3 million in number and comprise 43% of all male cancer survivors in the United States.1 These men face myriad unique oncologic, functional, emotional, and psychological issues that require evaluation and management throughout the survivorship phase of...

prostate cancer

ASCO Endorses American Cancer Society Prostate Cancer Survivorship Care Guidelines

As reported in the Journal of Clinical Oncology by Matthew J. Resnick, MD, of Vanderbilt University Medical Center, and colleagues, ASCO has endorsed the 2014 American Cancer Society Prostate Cancer Survivorship Care Guidelines.1,2 The ASCO endorsement panel was co-chaired by Dr. Resnick and David...

Karen E. Knudsen, PhD, Named Director of Sidney Kimmel Cancer Center at Thomas Jefferson University

Karen E. Knudsen, PhD, has been named the Director of the Sidney Kimmel Cancer Center (SKCC) at Thomas Jefferson University and the Hilary Koprowski Chair of the Department of Cancer Biology of the Sidney Kimmel Medical College of Thomas Jefferson University. Dr. Knudsen has been serving in these...

gynecologic cancers

American College of Physicians Releases Best Practice Advice for Cervical Cancer Screening in Average-Risk Women

In April 2015, the American College of Physicians (ACP) released its clinical advice guideline, Cervical Cancer Screening in Average-Risk Women: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians.1 The guideline aims to reduce the overuse of cervical...

colorectal cancer
issues in oncology

HPV-Related Anal Cancer on the Rise

More than 7,200 cases of anal cancer were diagnosed in 2014—approximately 2,600 in men and 4,600 in women—representing an increase of more than 4,000 from 8 years ago. In more than 90% of patients, infection with the human papillomavirus (HPV) is the cause, tagging anal cancer as a largely...

breast cancer

Managing Breast Cancer in 2015

Since 1990, we have seen an approximate 35% reduction in breast cancer mortality among women in the United States. Three protagonists can share this clinical success story: prevention, early detection, and better therapies. To shed light on the current state of breast cancer research and therapy,...

Expert Point of View: Elaine Mardis, PhD

Elaine Mardis, PhD, Co-director of The Genome Institute at Washington University School of Medicine, St. Louis, commented on the IMPaCT trial and the constraints of the U.S. health-care system. “The correct clinical trial has not yet been performed to demonstrate the clinical utility of genomic...

skin cancer
breast cancer
multiple myeloma
leukemia
colorectal cancer
prostate cancer
pancreatic cancer

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2015 Updates

For 2 decades, the NCCN Guidelines® have been recognized as the standard of cancer care in the United States, combining evidence, experience, and choice, so that multidisciplinary cancer treatment teams—including patients—are empowered to make informed decisions about cancer care,” said Robert W....

prostate cancer

Docetaxel Combined With Hormone Therapy Extends Survival in Advanced Prostate Cancer

Results from the STAMPEDE trial showed that the addition of docetaxel to standard hormone therapy improved overall survival by a median of 10 months over hormone therapy alone in men with newly diagnosed, advanced, hormone therapy–naive prostate cancer.1 The study also showed that zoledronic acid...

In Memoriam: Dorothy ‘Dottie’ Thomas

Dorothy “Dottie” Thomas was wife and research partner to 1990 Nobel laureate E. Donnall Thomas, MD, pioneer of the bone marrow transplant and former Director of the Clinical Research Division at Fred Hutchinson Cancer Research Center. Dr. and Mrs. Thomas formed the core of a team that proved bone...

In Memoriam: Lee W. Wattenberg, MD

One of the early giants in the field of cancer prevention, Lee W. Wattenberg, MD, published in 1966 what would be regarded as a landmark paper in the American Association for Cancer Research (AACR) journal Cancer Research. During his research, he reviewed 36 years of animal studies, looking at the...

In Memoriam: Eddie Reed, MD

Eddie Reed, MD, was a pioneer in the molecular pharmacology of DNA-damaging anticancer agents and the clinical development of paclitaxel for ovarian cancer. He graduated from Yale University School of Medicine in 1979, completed his internship and residency at Stanford University in 1981, and was...

A Tribute to James F. Holland, MD, in Celebration of His 90th Birthday

Far and away the best prize that life has to offer is the chance to work hard at work worth doing. —Theodore Roosevelt   Longevity, in and of itself, is not an accomplishment. Luck and good genes are just human lottery tickets. Most people fortunate enough to live long lives have a productive sweet ...

After a Long and Distinguished Career, Robert C. Young, MD, Shows No Sign of Slowing Down

Robert C. Young, MD, ASCO Past President, longtime leader of Fox Chase Cancer Center, and an internationally recognized expert in lymphoma and ovarian cancer, is a forward-looking doctor who is confident about something not in his future: retirement. “I’ll never quit working; I’m just not wired...

Global Leader in Drug Development John L. Marshall, MD, Calls for a Smarter War on Cancer

John L. Marshall, MD, a global leader in the research and treatment of gastrointestinal cancers, grew up in Lexington, Kentucky, in a family that put high value on education. As a young boy, science was already on his mind; he enjoyed the explorative nature that chemistry and biology offered....

myelodysplastic syndromes

Nationally Recognized Leader in Myeloid Malignancies, Alan F. List, MD, Has High Hopes for the Future of Oncology

The Tampa Bay area of Florida is a haven for golfers and fishermen looking to unwind under the warm tropical skies. And the clean highways stretching through the scenic west coast of Florida are also a perfect excuse for weekend motorcycle enthusiasts, such as Alan F. List, MD, the President and...

Pioneer in Combination Chemotherapy, Vincent T. DeVita, Jr, MD, Changed the Face of Modern Oncology

As a young boy growing up in the Bronx, Vincent T. DeVita, Jr, MD, admired the local iceman, a thick-muscled guy known as Nunzi, who used to carry a big block of ice on his shoulder with a set of tongs, and effortlessly slide it into the DeVitas’ icebox. “A friend once asked me what I wanted to be...

Bruce A. Chabner, MD, and His Innovative Pharmacology Research Led to the Development of Practice-Changing Therapies

Numerous challenges and milestones mark the course of an oncology career. Community doctors remember special patients, often speaking about a singular bond that is unique among a profession that deals with life and death daily. Researchers recount long hours of seeming futility and then the...

‘Father of Geriatric Oncology’ Lodovico Balducci, MD, Unearthed a New Understanding of Aging’s Effect on Cancer Treatment

At the 2007 ASCO Annual Meeting, Lodovico Balducci, MD, received the inaugural B.J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology. Called the “patriarch of geriatric oncology,” Dr. Balducci is widely known in the oncology community for his warm humor and thick Italian...

Carolyn R. ‘Bo’ Aldigé Reflects on 30 Years of Cancer Prevention

In 1985, Carolyn R. “Bo” Aldigé founded the Prevent Cancer Foundation in honor of her father, who had died the previous year of head and neck cancer. She started the Foundation in her kitchen with a typewriter, a sheath of carbon copy paper, and a telephone. “I quickly rented an office because a...

ASCO Announces First-Ever Clinical Trial

ASCO announced its first-ever clinical trial, which will offer patients with advanced cancer access to molecularly targeted cancer drugs and collect “real-world” data on clinical outcomes, to help learn the best uses of these drugs outside of indications approved by the U.S. Food and Drug...

supportive care

Expect Questions About Preventing Fractures After Stem Cell Transplant

Does the finding that the incidence of fractures is “compellingly higher” after hematopoietic stem cell transplantation mean that physicians counseling patients about transplant should feel compelled to discuss the fracture risks? Huifang Linda Lu, MD, PhD, the corresponding author of the study...

issues in oncology
hematologic malignancies
solid tumors

Incidence of Fractures Is ‘Compellingly Higher’ After Hematopoietic Stem Cell Transplantation

The incidence of fractures is “compellingly higher” after receiving hematopoietic stem cell transplantation, according to a retrospective study of patients receiving transplants for treatment of multiple myeloma, other hematologic malignancies, and some solid tumors (mostly breast and ovarian) as...

thyroid cancer
gastroesophageal cancer
lymphoma

Cancer Will Always Be Part of My Life

My first experience with cancer was when I was just 9 years old, and a lump the size of an egg popped out on the right side of my neck. A biopsy of the tumor found that it was Hodgkin lymphoma, and I was given huge doses of external-beam radiotherapy applied to my neck, chest, and underarm lymph...

Meir Wetzler, MD, RPCI Leukemia Chief, Dies at Age 60

Meir Wetzler, MD, Chief of the Leukemia Section at Roswell Park Cancer Institute and University at Buffalo (UB) Professor of Medicine, died on February 23 from injuries sustained during a skiing accident in Colorado. He was 60 years old. Nationally prominent in his field, Dr. Wetzler helped set...

colorectal cancer

Another Angiogenesis Inhibitor Shows Benefit in Metastatic Colorectal Cancer, but Where Do We Go Next?

The phase III RAISE trial—reported by Tabernero and colleagues in The Lancet Oncology1 and reviewed in this issue of The ASCO Post—demonstrated that ramucirumab ­(Cyramza), a fully human IgG1 monoclonal antibody to the vascular endothelial growth factor receptor 2 (VEGFR2) extracellular domain, in...

Daniel D. Von Hoff, MD, FACP, Receives the 2015 Wallace A. Reed, MD, Award

Daniel D. Von Hoff, MD, FACP, Distinguished Professor and Physician-in-Chief of the Translational Genomics Research Institute (TGen), received the 2015 Wallace A. Reed, MD, Award on May 29 from the Arizona Medical Association (ArMA). The award recognizes his accomplishments in advancing innovative...

Roswell Park Cancer Institute Appoints New Leadership Team

Roswell Park Cancer Institute recently announced a restructuring of its leadership. “In many cases, these new appointments represent Roswell Park Cancer Institute parlaying our own existing strengths and talents,” says President and CEO Candace Johnson, PhD. “Restructuring some of these positions...

Fulfilling NCI’s Commitment to Supporting the Best Science

On April 1, 2015, Douglas R. Lowy, MD, became Acting Director of the National Cancer Institute (NCI), succeeding ­Harold Varmus, MD, who left NCI to join the faculty of Weill Cornell Medical College in New York. (See “The Next Step in a Storied Career,” in the May 25, 2015 issue of The ASCO Post.)...

Advertisement

Advertisement




Advertisement